Johannesburg - Aspen Pharmacare Holdings [JSE:APN] said on Thursday that it expected its diluted normalised headline earnings per share from continuing operations to rise between 18% and 24% in the year ended June‚ from the previous comparable period.
Headline earnings per share are expected to climb between 21% and 27%‚ from the same period a year ago‚ while earnings per share are expected to between 4% and 10% higher.
The growth in earnings per share has been reduced as a result of capital profits on the disposal of discontinued businesses and products in the present year being lower than in the prior year‚ it said.
Headline earnings per share are expected to climb between 21% and 27%‚ from the same period a year ago‚ while earnings per share are expected to between 4% and 10% higher.
The growth in earnings per share has been reduced as a result of capital profits on the disposal of discontinued businesses and products in the present year being lower than in the prior year‚ it said.